[HTML][HTML] Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study
Sensory profiles are heterogeneous in neuropathic pain disorders, and subgroups of
patients respond differently to treatment. To further explore this, patients in the COMBO-DN
study were prospectively assessed by the Neuropathic Pain Symptom Inventory (NPSI) at
baseline, after initial 8-week therapy with either duloxetine or pregabalin, and after
subsequent 8-week combination/high-dose therapy. Exploratory post hoc cluster analyses
were performed to identify and characterize potential subgroups through their scores in the …
patients respond differently to treatment. To further explore this, patients in the COMBO-DN
study were prospectively assessed by the Neuropathic Pain Symptom Inventory (NPSI) at
baseline, after initial 8-week therapy with either duloxetine or pregabalin, and after
subsequent 8-week combination/high-dose therapy. Exploratory post hoc cluster analyses
were performed to identify and characterize potential subgroups through their scores in the …
以上显示的是最相近的搜索结果。 查看全部搜索结果